MYELOFIBROSIS (MF)
Clinical trials for MYELOFIBROSIS (MF) explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS (MF) trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS (MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink spleens in bone marrow cancer patients
Disease control CompletedThis study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for myelofibrosis patients: drug combo shows promise in shrinking spleens
Disease control CompletedThis study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill shows promise for rare blood cancer in early trial
Disease control CompletedThis early-phase trial tested a new drug called flonoltinib maleate in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow cancers. The main goals were to check safety, find the right dose, and see how the body processes the drug. Researchers hope this drug…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC